(AMG 510) 20170543
27 Aug 2018
AMG 510
NCT03600883
A Phase 1, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation.
Cancer Type | All cancers |
---|---|
Trial Type | Treatment |
Phase | Phase I |
Age Range | 18+ years |
Sex | Both |
Tumour Stream | Solid tumors |
Cancer Stage | Locally Recurrent or Locally Advanced |
Anticipated Start Date | 2018-08-27 |
Anticipated End Date | - |
Hospital | The Queen Elizabeth Hospital |
---|---|
Clinical Trial Coordinator | Pamela Cooper |
pamela.cooper@sa.gov.au | |
Phone | 08 8222 6410 |
Principal Investigator | Professor Tim Price |
Recruitment Status | Completed |
Keep up to date with the latest news and breakthroughs